Drug-induced Kidney Injury Model

April 14, 2025 updated by: Zhejiang Provincial People's Hospital

Establishment, Evaluation and Treatment Strategy of Drug-induced Kidney Injury Model

To establish the prediction model of renal dysfunction in patients with drug-induced renal injury and study the prognosis of different drug treatments

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Xiaolan Ye, Master
  • Phone Number: +86-0571-85893117
  • Email: yexl1120@126.com

Study Contact Backup

Study Locations

  • China
    • Zhejiang
      • Hangzhou, Zhejiang, China, 311121
        • Recruiting
        • Zhejiang Provincial People's Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Drug-induced acute kidney injury

Description

Inclusion Criteria:

  • Drug-induce acute kidney injury

Exclusion Criteria:

  • 1.Dialysis patients; 2.No baseline creatinine; 3.Obstructive AKI; 4.Clinical data were incomplete.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Drug induced acute kidney injury
Patients with acute kidney injury caused by the use of nephrotoxic drugs
Other: Observational study, no intervention
Observational study, no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Model performance metrics assessed by AUC-ROC, accuracy and F1-score using 10-fold cross-validation
Time Frame: through study completion, an average of 6 months
The prognosis of renal function was evaluated by measuring creatinine and proteinuria by laboratory tests. Predict outcomes using machine learning methods. And the prediction effect of the prediction model was evaluated by AUC-ROC, F1, accuracy and other indicators.
through study completion, an average of 6 months

Secondary Outcome Measures

Outcome Measure
Time Frame
The rate at which creatinine falls
Time Frame: 7 days, 1 month, 3 months after treatment
7 days, 1 month, 3 months after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zhejiang Provincial People's Hospital

Collaborators

Taizhou Enze Hospital
Ningbo Yinzhou District Second Hospital
Hangzhou Linping District first People's Hospital
Aksu district first People's Hospital
Wucheng District First People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 10, 2025

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

December 30, 2026

Study Registration Dates

First Submitted

March 10, 2025

First Submitted That Met QC Criteria

April 14, 2025

First Posted (Actual)

April 22, 2025

Study Record Updates

Last Update Posted (Actual)

April 22, 2025

Last Update Submitted That Met QC Criteria

April 14, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KT2024116

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

We will publish relevant research papers, patient data is not appropriate for public disclosure

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe